Are cancer patients on immunotherapy at a greater risk of severe COVID-19 infection?
4 February 2021
New research, led by Melanoma Institute Australia, has revealed that cancer patients treated with immunotherapy are not at a higher risk of developing severe COVID-19 infection compared to other cancer patients.
With more than 100 million* global cases of COVID-19 infection and the pandemic ongoing, this important finding will have implications for clinical decision-making in patients being treated with immunotherapy for cancer, including melanoma.
‘Previous studies have found that cancer patients infected with COVID-19 are more likely to develop a severe form of the illness and succumb to the disease compared to those without cancer,’ said first study author Dr Aljosja Rogiers, MIA’s Cameron Medical Oncology Fellow. ‘However, it was not known if patients with cancer on immunotherapy would have an increased or decreased risk of severe COVID-19, and this warranted investigation.’
Immunotherapy works by releasing the brakes on the immune system so that it can effectively target and destroy cancer cells. Knowing that immune cells can help fight viruses too meant that it was theoretically possible that immunotherapy may be helpful in reducing the severity of COVID-19 in patients with cancer.
However, immune cells release cytokines which increases inflammation: this has the potential to make the course of a COVID-19 infection worse. This clinical conundrum needed to be investigated to help guide treatment choices for clinicians during the pandemic.
Together with their international collaborators, the researchers found that treatment with immunotherapy does not further increase the risk of developing severe COVID-19 infection in patients with cancer. Their findings were recently published in the Journal for ImmunoTherapy of Cancer.
Publication: Rogiers A, Pires da Silva I, Tentori C, Tondini CA, Grimes JM, Trager MH, Nahm S, Zubiri L, Manos M, Bowling P, Elkrief A, Papneja N, Vitale MG, Rose AAN, Borgers JSW, Roy S, Mangana J, Pimentel Muniz T, Cooksley T, Lupu J, Vaisman A, Saibil SD, Butler MO, Menzies AM, Carlino MS, Erdmann M, Berking C, Zimmer L, Schadendorf D, Pala L, Queirolo P, Posch C, Hauschild A, Dummer R, Haanen J, Blank CU, Robert C, Sullivan RJ, Ascierto PA, Miller WH Jr, Stephen Hodi F, Suijkerbuijk KPM, Reynolds KL, Rahma OE, Lorigan PC, Carvajal RD, Lo S, Mandala M, Long GV. Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition. J Immunother Cancer. 2021 Jan;9(1):e001931.
*Update data from Johns Hopkins Coronavirus Resource Center. COVID-19 Map. Available: https://coronavirus.jhu.edu/map.html [Accessed 3 Feb 2021].
Australian researchers have successfully trialled a combination of new treatments to prevent melanoma from spreading to distant organs.
A new treatment that combines an antibody with a cancer-killing virus improves outcomes for patients with advanced melanoma, an international clinical trial has shown.
It feels like groundhog day - another reality TV show, another batch of blatantly sunburnt contestants.
Wouldn’t it be great if your doctor could know if you would respond to treatment before you even had it?
In our latest research update we showcase research in survival estimates, uncover biomarkers, and reveal practice-changing research in surgery and medical oncology.
Senior Clinical Trial Coordinators, like Sarah Lane, support melanoma patients throughout the clinical trial process.
Melanomas are often hard to differentiate from moles. But new technology is helping to improve accuracy of diagnosis.
We are excited to announce that SunSense will proudly be an official supporter of Melanoma Institute Australia. SunSense is an Australian, family owned business.
Five years ago Julie Randall was diagnosed with melanoma and was given months to live. The melanoma had spread throughout her body. The doctors said it was incurable and she’d be lucky if she survived the next nine months. Julie, a patient at Melanoma Institute Australia under Professor Georgina Long was placed on an experimental drug trial. To watch the entire program, visit 9now.com or click here.
Meet our latest Surgical Oncology Fellow, Eva Nagy, to find out more about life as a surgical oncologist, why she came to MIA and what she hopes to achieve.
Melanoma research at ASCO this year focussed on the more precise use of current treatments to ensure optimal treatment for each patient.
MIA recently demonstrated that reflectance confocal microscopy is a useful tool in the clinic to diagnose suspicious-looking lesions in the mouth.
New research is likely to change the way melanoma is managed in many patients by reducing the need for major surgery and its associated morbidity and cost.
Researchers from MIA will present their latest research findings to the world’s largest oncology conference in early June.
Australian researchers pioneer life-extending treatment for advanced melanoma patients with brain tumours
Australian researchers are the first to demonstrate that patients with advanced melanoma which has spread to the brain can have increased life expectancy and possibly even beat the disease.
Melanoma March 2017 - that's a wrap! Thank you to everyone that helped make it happen.
Thank you so much to all those who contributed in a variety of ways to Melanoma March 2017 in 17 different locations and more around the country! You have contributed to getting the Big Data for Melanoma national Research Project happening!
By looking at the ‘dark matter’ of the genome, new research has found that genetic changes in acral and mucosal melanoma are completely different to mutations found in skin melanoma.
‘Slip, slop, slap’ is synonymous with being Australian and playing it safe in the sun. These sun smart rules reduce our chances of getting melanoma of the skin. However, new research tells a different story for those affected by rarer forms of melanoma.